GSK and Lithium


Lithium – Photograph by W.Oelen (CC BY S.A 3.0)

We looked at Glycogen Synthase Kinase 3 in previous posts. This enzyme has been referenced in Small and Duffy’s Dual Pathway hypothesis of Alzheimer’s Disease.

Beurel and colleagues review the regulation and actions of GSK 3 as well as diseases that have been linked to GSK 3 in this paper.

The authors identify two key findings that have led to GSK being a focus for research

  1. The involvement of GSK 3 in Tau phosphorylation – a process which has been implicated in Alzheimer’s Disease.
  2. GSK 3 is a key target for Lithium.

The story is a lot more complex than this however as GSK is involved in many different pathways.

Index: There are indices for the TAWOP site here and here

Twitter: You can follow ‘The Amazing World of Psychiatry’ Twitter by clicking on this link.

TAWOP Channel: You can follow the TAWOP Channel on YouTube by clicking on this link.

Responses: If you have any comments, you can leave them below or alternatively e-mail

Disclaimer: The comments made here represent the opinions of the author and do not represent the profession or any body/organisation. The comments made here are not meant as a source of medical advice and those seeking medical advice are advised to consult with their own doctor. The author is not responsible for the contents of any external sites that are linked to in this blog.

Conflicts of Interest: *For potential conflicts of interest please see the About section.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s